VectivBio (VECT) Competitors $16.85 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends VECT vs. NAMS, CGON, TWST, AMPH, MIRM, APGE, WVE, AKRO, EVO, and HRMYShould you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include NewAmsterdam Pharma (NAMS), CG Oncology (CGON), Twist Bioscience (TWST), Amphastar Pharmaceuticals (AMPH), Mirum Pharmaceuticals (MIRM), Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Evotec (EVO), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. VectivBio vs. NewAmsterdam Pharma CG Oncology Twist Bioscience Amphastar Pharmaceuticals Mirum Pharmaceuticals Apogee Therapeutics Wave Life Sciences Akero Therapeutics Evotec Harmony Biosciences NewAmsterdam Pharma (NASDAQ:NAMS) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Do analysts prefer NAMS or VECT? NewAmsterdam Pharma currently has a consensus target price of $33.80, suggesting a potential upside of 35.74%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in NAMS or VECT? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, NAMS or VECT? NewAmsterdam Pharma has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Is NAMS or VECT more profitable? Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A VectivBio N/A N/A N/A Does the media prefer NAMS or VECT? In the previous week, NewAmsterdam Pharma had 19 more articles in the media than VectivBio. MarketBeat recorded 19 mentions for NewAmsterdam Pharma and 0 mentions for VectivBio. NewAmsterdam Pharma's average media sentiment score of 0.57 beat VectivBio's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Overall Sentiment NewAmsterdam Pharma Positive VectivBio Neutral Which has stronger valuation & earnings, NAMS or VECT? VectivBio has higher revenue and earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$14.09M159.07-$176.94MN/AN/AVectivBio$27.34M20.97-$93.74MN/AN/A Does the MarketBeat Community prefer NAMS or VECT? NewAmsterdam Pharma received 8 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes18100.00% Underperform VotesNo VotesVectivBioOutperform Votes1043.48% Underperform Votes1356.52% SummaryNewAmsterdam Pharma beats VectivBio on 10 of the 13 factors compared between the two stocks. Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades Get VectivBio News Delivered to You Automatically Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VECT vs. The Competition Export to ExcelMetricVectivBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.24M$2.93B$5.17B$8.74BDividend YieldN/A1.86%5.18%4.08%P/E RatioN/A18.0870.3714.07Price / Sales20.97284.521,270.9686.98Price / CashN/A166.9239.7135.24Price / Book2.694.006.485.93Net Income-$93.74M-$42.42M$119.82M$225.73M7 Day PerformanceN/A-10.63%-5.13%-1.34%1 Month PerformanceN/A-5.81%-2.71%1.15%1 Year PerformanceN/A24.19%31.11%24.02% VectivBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeNAMSNewAmsterdam Pharma3.0112 of 5 stars$24.90-0.3%N/A+150.5%$2.24B$14.09M0.0057Short Interest ↑News CoverageHigh Trading VolumeCGONCG Oncology3.1959 of 5 stars$32.90-7.3%N/AN/A$2.22B$200,000.000.0061Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageTWSTTwist Bioscience3.4797 of 5 stars$36.89-5.3%N/A+93.4%$2.16B$245.11M-9.66990Upcoming EarningsInsider SellingNews CoverageHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.7791 of 5 stars$44.61-1.0%N/A-20.6%$2.14B$644.40M14.871,761Insider SellingMIRMMirum Pharmaceuticals4.2716 of 5 stars$44.50-3.8%N/A+46.8%$2.14B$186.37M-22.03140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageAPGEApogee Therapeutics2.3218 of 5 stars$47.25-7.4%N/A+181.1%$2.13BN/A-19.5291Analyst ForecastAnalyst RevisionNews CoverageWVEWave Life Sciences4.8728 of 5 stars$13.67-8.9%N/A+149.0%$2.08B$113.31M-12.32240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageAKROAkero Therapeutics4.0331 of 5 stars$28.09-5.6%N/A+94.5%$1.96BN/A-7.4930Earnings ReportShort Interest ↓Analyst RevisionNews CoverageEVOEvotec1.0274 of 5 stars$5.44+6.7%N/A-44.7%$1.93B$845.74M0.005,061Short Interest ↓News CoverageGap UpHigh Trading VolumeHRMYHarmony Biosciences4.8495 of 5 stars$33.22+0.7%N/A+28.5%$1.89B$582.02M15.74200Short Interest ↓ Related Companies and Tools Related Companies NAMS Alternatives CGON Alternatives TWST Alternatives AMPH Alternatives MIRM Alternatives APGE Alternatives WVE Alternatives AKRO Alternatives EVO Alternatives HRMY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VECT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VECT with Qtrade Free VECT Stock Alerts